^
Association details:
| Biomarker: | PRMT7 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P70.03 - Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance
Published date:
08/18/2021
Excerpt:
The CBM identified that novel amplified segments of Chromosome 6p were associated with non-responsiveness to gemcitabine and platinum therapy....Besides 6p amplification, PRMT7 deletion was also associated with gemcitabine resistance.